ImmunityBio, Inc. (IBRX) Financials

IBRX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 504.5 million 1.1 billion
2023-09-30 432.4 million 843.1 million
2023-06-30 291.2 million 936.4 million
2023-03-31 343.4 million 875.1 million

IBRX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -123.2 million 12.8 million
2023-09-30 -93.1 million 14.4 million
2023-06-30 -88.3 million 11.1 million
2023-03-31 -92.7 million 10.9 million

IBRX Net Income

No data available :(

IBRX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 266.5 million - 45.2 million
2023-09-30 189.8 million - 43.7 million
2023-06-30 46.0 million - 50.5 million
2023-03-31 91.3 million - 49.1 million

IBRX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 670.9 million
2023-09-30 498.4 million
2023-06-30 437.5 million
2023-03-31 428.4 million

IBRX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 8.0 million 51.0 million 33.1 million -
2023-09-30 5.7 million 48.4 million 31.8 million -
2023-06-30 8.5 million 53.2 million 32.0 million -
2023-03-31 8.4 million 79.3 million 32.7 million -

IBRX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 139000 4.6 million
2023-09-30 82000 4.6 million
2023-06-30 41000 6.3 million
2023-03-31 360000 6.3 million

IBRX

Price: $9.15

52 week price:
1.25
9.15

Earnings Per Share: -1.15 USD

P/E Ratio: -4.40

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 1.2 million

Market Capitalization: 4.1 billion

Links: